Biotechnology

KALA BIO

KALA BIO released FY2025 Q3 earnings on November 19 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.074 (forecast USD -1.01)

KALA BIO released FY2025 9 Months Earnings on November 19 (EST), with actual revenue of USD 0 and EPS of USD -4.1966

KALA BIO released FY2025 Semi-Annual earnings on August 8, 2025 (EST), with actual revenue of USD 0 and EPS of USD -3.1263

KALA BIO released FY2025 Q2 earnings on August 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.7126 (forecast USD -1.7033)

KALA BIO's CFO Sells Shares

H.C. Wainwright lowers KALA BIO target price to $12

KALA BIO released FY2025 Q1 earnings on May 14, 2025 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD -1.4098 (forecast USD -2.03)

Kala Bio Reports Q1 EPS of -$1.41

KALA BIO released FY2024 Q4 earnings on March 31 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.7413 USD (forecast -2.28 USD)

KALA BIO released FY2024 annual earnings on March 31 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -10.145 USD (forecast -10.835 USD)

KALA BIO released FY2024 9 Months earnings on November 12 (EST), actual revenue USD 0, actual EPS USD -9.2922

KALA BIO released FY2024 Q3 earnings on November 12 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.934 USD (forecast -2.43 USD)

KALA BIO released FY2024 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.1969 (forecast USD -2.89)

KALA BIO released FY2023 Q4 earnings on March 29 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -3.1804 USD (forecast -3.62 USD)

Structure Therapeutics

Cemtrex

Wave Life Sciences

Fulcrum Therapeutics

Kymera Therapeutics

Top Wealth

Paranovus ENT Tech

iBio

Immutep

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap